Antía Cousillas Castiñeiras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antía Cousillas Castiñeiras has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Ana Fernández Montes
Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
3 shared publications - Paula González Villarroel
Alvaro Cunqueiro Hospital, Vigo, Spain
3 shared publications Ana Fernández Montes
Medical Oncology Department, University Hospital of Ourense, Ourense, Spain
2 shared publicationsJosé Carlos Méndez Méndez
Medical Oncology Department, Sanatorio Nosa Señora dos Ollos Grandes, Lugo, Spain
2 shared publications- Mercedes Salgado
Medical Oncology Department, Complexo Hospitalario de Ourense, Ourense, Spain
2 shared publications Nieves Martínez Lago
Medical Oncology Department, Hospital Arquitecto Marcide, Ferrol, Spain
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
- 1 September 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Open AccessReal-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
- Open Access
- 17 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1773
Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary. To evaluate low molecular weight heparin (LMWH) for primary thromboprophylaxis in metastatic CRC outpatients receiving first-line systemic cancer therapy. PROTINCOL (NCT05625932) is a randomized, open-label (PROBE), multicenter study. Patients will receive tinzaparin (75 IU/kg) or no pharmacological prophylaxis for 4 months and will be stratified based on: BRAF/RAS mutation, primary resection tumor and antiangiogenic therapy. The study outcomes will be assessed by a blinded central independent adjudication committee. The primary efficacy endpoints will include the cumulative incidence of any venous thromboembolism (VTE) event (symptomatic or incidental) including symptomatic central venous catheter VTE. Secondary variables will be clinically relevant bleedings, health-related quality of life and the predictive value of validated risk assessment scales of VTE, including the genetic risk score (TIC-ONCO). Our hypothesis is that prophylactic LMWH will reduce the 55% relative risk to an estimated VTE incidence of 13.5%. A total of 526 patients will be required. Risk prediction of chemotherapy-associated VTE is a compelling challenge in oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Patients with a single type of metastatic cancer with a high risk of VTE will be selected for study inclusion. For the first time in ambulatory prophylaxis of cancer-associated thrombosis, a precision medicine approach will be used in a clinical trial. If the individualization of antithrombotic prophylaxis can reduce the complications of outpatient cancer treatment and be cost effective, it would be of great value in the future care of patients with metastatic CRC. NCT05625932. Registered on 15 Nov 2022. The trial started recruitment on March 2023.
- 17 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1773
Open AccessTinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation of the risk/benefits of anticoagulant prophylaxis is necessary. To evaluate low molecular weight heparin (LMWH) for primary thromboprophylaxis in metastatic CRC outpatients receiving first-line systemic cancer therapy. PROTINCOL (NCT05625932) is a randomized, open-label (PROBE), multicenter study. Patients will receive tinzaparin (75 IU/kg) or no pharmacological prophylaxis for 4 months and will be stratified based on: BRAF/RAS mutation, primary resection tumor and antiangiogenic therapy. The study outcomes will be assessed by a blinded central independent adjudication committee. The primary efficacy endpoints will include the cumulative incidence of any venous thromboembolism (VTE) event (symptomatic or incidental) including symptomatic central venous catheter VTE. Secondary variables will be clinically relevant bleedings, health-related quality of life and the predictive value of validated risk assessment scales of VTE, including the genetic risk score (TIC-ONCO). Our hypothesis is that prophylactic LMWH will reduce the 55% relative risk to an estimated VTE incidence of 13.5%. A total of 526 patients will be required. Risk prediction of chemotherapy-associated VTE is a compelling challenge in oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Patients with a single type of metastatic cancer with a high risk of VTE will be selected for study inclusion. For the first time in ambulatory prophylaxis of cancer-associated thrombosis, a precision medicine approach will be used in a clinical trial. If the individualization of antithrombotic prophylaxis can reduce the complications of outpatient cancer treatment and be cost effective, it would be of great value in the future care of patients with metastatic CRC. NCT05625932. Registered on 15 Nov 2022. The trial started recruitment on March 2023.
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (6) , 3702-3713
Vitamin D-regulated miRNA expression in tumoral and normal adjacent tissue of localized gastric cancer patients: the impact on survival and time to relapse
Background: Gastric cancer (GC) is driven by genetic, epigenetic, and environmental factors, with dysregulated microRNAs (miRNAs) influencing key biological processes and vitamin D signaling through vitamin D receptor modulation, impacting tumor prognosis. The aim of this study is to correlate the expression of vitamin D-related miRNAs in tumor tissue and normal adjacent tissue (NAT) in GC with patient survival. Methods: The study involved 77 patients with localized GC, with time to relapse (TTR) and overall survival (OS) as primary and secondary endpoints, respectively. The study investigated miRNA expression levels in NAT and tumor and their association with patient characteristics. Results: The analysis revealed that miR-106b, miR-181b-5p, miR-181a-5p and miR-181d-5p were upregulated in tumor tissue, whereas miR-143 and miR-145 were downregulated. Patients with vitamin D deficiency (levels Conclusions: The study concludes that miRNA dysregulation in non-neoplastic gastric mucosa suggests these tissues may be cancer-prone environments.
- 1 June 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (6) , 3702-3713
Open AccessVitamin D-regulated miRNA expression in tumoral and normal adjacent tissue of localized gastric cancer patients: the impact on survival and time to relapse
Background: Gastric cancer (GC) is driven by genetic, epigenetic, and environmental factors, with dysregulated microRNAs (miRNAs) influencing key biological processes and vitamin D signaling through vitamin D receptor modulation, impacting tumor prognosis. The aim of this study is to correlate the expression of vitamin D-related miRNAs in tumor tissue and normal adjacent tissue (NAT) in GC with patient survival. Methods: The study involved 77 patients with localized GC, with time to relapse (TTR) and overall survival (OS) as primary and secondary endpoints, respectively. The study investigated miRNA expression levels in NAT and tumor and their association with patient characteristics. Results: The analysis revealed that miR-106b, miR-181b-5p, miR-181a-5p and miR-181d-5p were upregulated in tumor tissue, whereas miR-143 and miR-145 were downregulated. Patients with vitamin D deficiency (levels Conclusions: The study concludes that miRNA dysregulation in non-neoplastic gastric mucosa suggests these tissues may be cancer-prone environments.
- Open Access
- 12 July 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12 months for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, respectively, log-rank p = 0.9. The most common grade 3–4 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS/NRAS/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine/tipiracil, NLR, CEA, and alkaline phosphatase. The model’s bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636–0.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, respectively. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series.
- 12 July 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Open AccessPrediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor burden and indolent disease. Other models in refractory mCRC are the FAS-CORRECT and Colon Life nomogram. The main objective was to externally validate the prognostic factors of the RECOURSE and FAS-CORRECT trials, and the Colon Life nomogram in a multicenter, real-world series of mCRC treated in 3rd and successive lines with trifluridine/tipiracil. The secondary aim was to develop an OS predictive model, TAS-RECOSMO. Between 2016 and 2019, 244 patients were recruited. Median OS was 8.15 vs 8.12 months for the poor (85% of the subjects) and good (15%) prognosis groups from the RESOURCE trial, respectively, log-rank p = 0.9. The most common grade 3–4 toxicities were neutropenia (17%), asthenia (6%), and anemia (5%). The AFT lognormal model TAS-RECOSMO included six variables: ECOG-PS, KRAS/NRAS/BRAF mutation status, time between diagnosis of metastasis and beginning of trifluridine/tipiracil, NLR, CEA, and alkaline phosphatase. The model’s bootstrapped bias-corrected c-index was 0.682 (95% CI, 0.636–0.722). The factors from the Colon Life model, FAS-CORRECT, and RECOURSE displayed a c-index of 0.690, 0.630, and 0.507, respectively. TAS-RECOSMO, FAS-CORRECT, and the Colon Life nomogram appear to predict OS in patients with refractory mCCR who begin trifluridine/tipiracil treatment in the real world. The prognostic groups of the RECOURCE RCT were unable to capture the situation of real-world subjects treated with trifluridine/tipiracil in this series.
- Open Access
- 3 June 2021
- Published by MDPI AG in Healthcare
- Vol. 9 (6) , 665
Do Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method
Background: In recent years, abundant scientific evidence has been generated based on clinical trials (CT) in the field of oncology. The general objective of this paper is to find out the extent to which decision making is based on knowledge of the most recent CT. Its specific objectives are to pinpoint difficulties with decision making based on the CT performed and find out the motivations patients and clinicians have when taking part in a CT. Methodology: Combined, prospective study, based on the Delphi method. A lack of correspondence between the people who take part in CT and patients who come for consultation has been identified. A need for training in analysing and interpreting CT has also been identified and a lack of trust in the results of CT financed by the pharmaceutical industry itself has been perceived. Conclusions: There is a difficulty in selecting oncological treatment due to the lack of correspondence between the patients included in the CT and patients seen in consultation. In this process, real world data studies may be highly useful, as they may provide this group with greater training in interpreting CT and their results.
- 3 June 2021
- Published by MDPI AG in Healthcare
- Vol. 9 (6) , 665
Open AccessDo Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method
Background: In recent years, abundant scientific evidence has been generated based on clinical trials (CT) in the field of oncology. The general objective of this paper is to find out the extent to which decision making is based on knowledge of the most recent CT. Its specific objectives are to pinpoint difficulties with decision making based on the CT performed and find out the motivations patients and clinicians have when taking part in a CT. Methodology: Combined, prospective study, based on the Delphi method. A lack of correspondence between the people who take part in CT and patients who come for consultation has been identified. A need for training in analysing and interpreting CT has also been identified and a lack of trust in the results of CT financed by the pharmaceutical industry itself has been perceived. Conclusions: There is a difficulty in selecting oncological treatment due to the lack of correspondence between the patients included in the CT and patients seen in consultation. In this process, real world data studies may be highly useful, as they may provide this group with greater training in interpreting CT and their results.
- Open Access
- 16 February 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (14) , 1777-1791
Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, re...
- 16 February 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (14) , 1777-1791
Open AccessReal-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, re...